Clinical Trials in Ramos Mejía, Buenos Aires
5 recruiting
Showing 1–5 of 5 trials
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled492 locationsNCT07517263
Recruiting
Phase 3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals288 enrolled83 locationsNCT06880770
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled318 locationsNCT06528314
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
MASH With FibrosisNASH With Fibrosis
Akero Therapeutics, Inc1,650 enrolled349 locationsNCT06215716
Recruiting
Phase 3
Efficacy of INM004 in Children With STEC-HUS
Hemolytic-Uremic Syndrome
Inmunova S.A.220 enrolled52 locationsNCT06389474